Golden
Kala Pharmaceuticals

Kala Pharmaceuticals

A biopharmaceutical company that develops nanotherapeutic treatments for ocular diseases and other eye related conditions

Kala Pharmaceuticals is a biotechnology company headquartered in Waltham, Massachusetts and was founded in 200 by Justin Hanes and Robert Langer.



The name Kala, from Kala Pharmaceuticals, comes from the Kalalau trail in Kauai, Hawaii, known for its strenuous path and difficult terrain but also for its beauty. The company is developing and commercializing therapeutics using their proprietary mucus-penetrating particle (MPP) technology with an initial focus on eye disease. MPPs are selectively sized with proprietary coatings, two characteristics the company believes enable even distribution of drug particles on mucosal surfaces and increase drug delivery to target tissues. 



Kala created nanosuspensions of loteprednol etabonate (LE), a corticosteroid, with their MPP technology to generate two lead product candidates, INVELTYS (PI-121 1.0%) and KPI-121 0.25%. IVELTYS is for treating inflammation and pain after ocular surgery and KPI-121 0.25% is for temporary relief of dry eye disease signs and symptoms. 



Iveltys which won FDA approval in 2018, is a new formulation of a topical steroid from Bausch Health which did not use nanoparticle technology. Iveltys is claimed to have better efficacy, safety and convenience for patients. Preliminary results from a Phase 3 study on KPI-121 are expected to be available in late 2019.

Funding

Series A

On February 28, 2013 Kala Pharmaceuticals completed their series A funding round with $11.5 million in funding from Crown Venture Fund (lead investor), Crown family of Chicago, Lux Capital Management, Polaris Venture Partners, and Third Rock Ventures. 

Series B

On April 23, 2014 Kala Pharmaceuticals completed their series B funding round with $22.5 million in funding from Ysios Capital (lead investor), Third Rock Ventures, Polaris Partners, Lux Capital, Crown Venture Fund, and AbbVie Biotech Ventures. 

Series C

On April 13, 2016 Kala Pharmaceuticals completed their series C funding round with $68 million in funding from Longitude Capital (lead investor), Wellington Management, Vivo Capital, RA Capital Management, Polaris Partners, Lux Capital, and CAM Capital. 

Timeline

April 13, 2016

Series C funding round

On April 13, 2016 Kala Pharmaceuticals completed their series C funding round with $68 million in funding from Longitude Capital (lead investor), Wellington Management, Vivo Capital, RA Capital Management, Polaris Partners, Lux Capital, and CAM Capital. 

April 23, 2014

Series B funding round

On April 23, 2014 Kala Pharmaceuticals completed their series B funding round with $22.5 million in funding from Ysios Capital (lead investor), Third Rock Ventures, Polaris Partners, Lux Capital, Crown Venture Fund, and AbbVie Biotech Ventures. 

February 28, 2013

Series A funding round

On February 28, 2013 Kala Pharmaceuticals completed their series A funding round with $11.5 million in funding from Crown Venture Fund (lead investor), Crown family of Chicago, Lux Capital Management, Polaris Venture Partners, and Third Rock Ventures. 

Funding rounds

3 Results
Funding round
Funding round
Funded company
Funded company
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Rob Paull

Founder



Further reading

Title
Author
Link
Type
Date

Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration

Business Wire

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References